At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune responses and clinical outcomes in STAND, a randomised phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer after local therapy failure.
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews
Advertisement